Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
  • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

• the present invention relates to a transduction system comprising a rep-negative AAV vector and its use.
• Transduction refers to the transmission of genes using viruses as a vector. Transduction is often used to insert genes into the genome
• viruses are e.g. Adeno-associated viruses (AAVs) are used.
• AAVs Adeno-associated viruses
• AAVs are single-stranded DNA viruses belonging to the parvovirus family. For their replication, AAVs need helper viruses, especially adenoviruses or
• AAVs integrate into the host cell genome, particularly at a specific location on chromosome 19.
• the genome of AAVs is linear and has a length of approximately 4680 nucleotides. This comprises two reading frames which code for a structural and a non-structural gene.
• the structural gene is called the cap gene. This is under the control of the P40 promoter and codes for three capsid proteins.
• the non-structural gene is referred to as the rep gene and codes for the Rep proteins, Rep 78, Rep 68, Rep 52 and Rep 40. The former two are expressed under the control of the P5 promoter, while the expression of Rep 52 and Rep 40 is under the control of the P19 promoter.
• the functions of the Rep proteins include in the regulation of replication and transcription of the AAV genome.
• the present invention is therefore based on the object of providing a means by which a foreign DNA can be specifically integrated into the genome of cells.
• the present invention thus relates to a transduction system comprising: (a) a rep-negative AAV vector containing a foreign DNA, and
• the present invention is based on the applicant's finding that AAVs lacking the rep gene do not integrate into the genome of cells.
• rep negative AAV vector refers to any AAV, i.e. Virus particles, and their DNA, which are rep negative. The latter means that there is no or only a defective rep gene.
• Conventional methods can be used to provide a rep-negative AAV vector. For example, an AAV DNA can be changed by specific mutagenesis in the rep gene so that it becomes defective, or the rep gene is deleted by special restriction cleavage and ligation.
• a rep-negative AAV DNA can then be transfected into cells expressing an AAV rep gene, and after infection with a helper virus, rep-negative AAVs, i.e. Virus particles.
• the term "foreign DNA” refers to any DNA that can be integrated in a rep-negative AAV vector.
• the foreign DNA can be non-coding or coding.
• the foreign DNA can be a regulatory element of DNA replication and / or transcription.
• the foreign DNA can code for a diagnostic and / or therapeutic protein. Examples of one therapeutic proteins are tumor necrosis factor, interferons, interleukins, lymphokines, growth factors, plasma proteins and receptors.
• the foreign DNA can be inserted anywhere in the rep-negative AAV vector. It can be advantageous if the foreign DNA is present in or instead of the rep gene. It can also be advantageous if there are several foreign DNAs.
• agent providing AAV Rep protein includes any agent that can provide an AAV Rep protein, particularly Rep 78 or Rep 68, or a portion thereof.
• the agent can be an AAV rep
• rep-DNA Protein or a part of it expressible DNA (rep-DNA). It is favorable if the expression of the rep-DNA is under the control of an inducible promoter, such as an antibiotic or tissue-specific promoter.
• the rep DNA can be comprised of the genome of an AAV virus particle. It is favorable if the genome contains a defective (deleted) cap gene or an inducible one
• the genome and the corresponding AAV virus particle can also be an agent in the above sense.
• the agent can be an AAV-Rep protein, in particular Rep 78 or Rep 68, itself or a part thereof or a fusion protein which contains an AAV-Rep protein or a part thereof.
• Such proteins can be provided by customary methods.
• components (a) and (b) can be connected to one another. Such a connection can be made by conventional methods. Lying z. B. the AAV vector of component (a) as virus
• the AAV vector is modified chemically or enzymatically.
• biotinylated ie biotin or a biotinylated anti-AAV antibody, such as an antibody directed against the AAV proteins VP-1, VP-2 or VP-3, are bound to the AAV vector.
• the rep-expressing DNA is mixed with DNA-binding substances, such as organic polycations, for example polylysine and / or polyornithine, or heterologous polycations with several different, positively charged amino acids.
• An above transduction system is suitable for transducing cells.
• the cells can be of any kind and descent.
• the cells can be present individually or in a bandage, such as a tissue or organ.
• the cells can also be present in or outside an organism. In the latter case, the cells can be kept in culture.
• the cells can be healthy cells, diseased cells such as virus-infected cells or cells infected with microorganisms or single cells, or tumor cells.
• the transduction of the cells can be carried out by conventional methods. Becomes a
• the cells can be infected with the transduction system.
• the transduction system can e.g. can be introduced into the cells by transfection, lipofection or electroporation.
• the cells can be infected with the virus particles.
• the cells can be infected with the AAV vector or the agent and the DNA can be introduced into the cells as indicated above.
• the AAV vector and the agent are each present as DNA, they can be introduced into the cells as indicated above.
• the agent is also in the form of an AAV-Rep protein or a part thereof or as a fusion protein which contains an AAV-Rep protein or a part thereof, the agent can be introduced into the cells, for example by lipofection become.
• the present invention can be used to transduce cells that are inside or outside an organism.
• the present invention is particularly suitable for transducing cells from a tumor material that has been removed without these cells having to be brought into culture beforehand.
• the present invention is therefore ideally suited for use in gene therapy, in particular of monogenic diseases, such as hemoglobin abnormalities, cystic fibrosis, subtypes of Parkinson's disease and hemophilia, of AIDS and cancer.
• monogenic diseases such as hemoglobin abnormalities, cystic fibrosis, subtypes of Parkinson's disease and hemophilia, of AIDS and cancer.
• the invention is illustrated by the following example.
• transduction system As a transduction system according to the invention, one is used in which components (a) and (b) are separated from one another.
• Expression plasmid pRc / CMV (Invitrogen) transfected, which contains an AAV rep gene under the control of the CMV promoter.
• AAV rep gene under the control of the CMV promoter.
• the expression of the AAV-rep gene is determined by an antibody directed against AAV-Rep 78 in the immunoblot.
• Vector i.e. a virus particle that contains an expressible foreign DNA, e.g. contains a DNA coding for a B7 protein.
• a specific integration of the foreign DNA on chromosome 19 is obtained. This is proven by standard procedures. Expression of the B7 protein is also obtained. This is demonstrated by an antibody directed against the B7 protein.
• tetR is a tetracycline repressor
• VP1 6 is the transactivation domain of the VP1 6 molecule of HSV.
• the second expression plasmid, pUHD10-3 contains an AAV rep gene which is under the control of a promoter which is induced by the tetR-VP1 6 fusion protein. This induction is obtained when the tetracycline
• the detection of the transfection is determined via the expression of a neomycin resistance gene on the first expression plasmid and the expression of the rep gene on the second expression plasmid.
• the transfected cells are then infected with the rep-negative AAV vector from (a), which contains a foreign DNA coding for a B7 protein. After removal of tetracycline from the medium a specifi ⁇ specific integration is obtained of the foreign DNA on chromosome 1. 9 This is proven by standard procedures. Expression of the

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Genetics & Genomics (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Immunology (AREA)
• General Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Plant Pathology (AREA)
• Biochemistry (AREA)
• Oncology (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Psychology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• AIDS & HIV (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=7787450

Family Applications (1)

Country Status (5)

Families Citing this family (196)

Family Cites Families (9)

• 1996
  • 1996-03-06 DE DE19608753A patent/DE19608753C1/de not_active Expired - Fee Related
• 1997
  • 1997-03-06 US US09/142,289 patent/US6207453B1/en not_active Expired - Fee Related
  • 1997-03-06 JP JP9531353A patent/JP2000506726A/ja not_active Ceased
  • 1997-03-06 EP EP97918010A patent/EP0891429A2/de not_active Withdrawn
  • 1997-03-06 WO PCT/DE1997/000447 patent/WO1997032989A2/de not_active Application Discontinuation
• 2001
  • 2001-01-31 US US09/773,302 patent/US6440742B1/en not_active Expired - Fee Related
• 2002
  • 2002-08-12 US US10/218,280 patent/US20020192826A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events